Predictive biomarkers for EGFR therapy

A. Sakurada, M. S. Tsao

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)

Abstract

The results of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21 study, a phase III, randomized, placebo-controlled trial of erlotinib in patients with advanced NSCLC who had failed first-line or second-line chemotherapy, provided new treatment options for lung cancer. Given that only a small percentage of patients may benefit from treatment with inhibitors that target the EGF receptor (EGFR), substantial effort has been devoted to identifying biomarkers that are predictive of the highest likelihood of benefit from these drugs. Several markers, including EGFR tyrosine kinase domain mutation, EGFR gene copy number and KRAS mutation, have been investigated extensively, but results obtained to date remain controversial. This feature review discusses available data and the basis for the controversies.

Original languageEnglish
Pages (from-to)34-38
Number of pages5
JournalIDrugs
Volume12
Issue number1
Publication statusPublished - 2009 Jan 1

Keywords

  • Biomarker
  • Erlotinib
  • Gefitinib
  • NSCLC
  • Targeted therapy
  • Tyrosine kinase receptor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Predictive biomarkers for EGFR therapy'. Together they form a unique fingerprint.

Cite this